Italy: High Earners "Should Quit NHS"

8 September 1996

Italian Health Minister Rosy Bindi wants to expel from health service provision people earning over 70 million lire ($46,284) a year. Her call came as Italy's health service moved nearer the center of the tense political debate underway in Rome over the 1997 state budget.

The Health Ministry is now reviewing urgently a range of proposals for a new ticket system of patient charges, which it is understood would be linked directly to income levels. Clarity was expected soon after high-level talks were due to take place last week between Ms Bindi, President Romano Prodi, Treasury Minister Ciampi and Finance Minister Visco.

Apart from issues relating to a hospital ticket plan, Ms Bindi and the government have agreed other proposals now being finalized, including the incompatibility of health service treatment by doctors in hospitals and university clinics with "private professional activity" (Marketletter September 2). Savings of 1,400-1,500 billion lire ($925.6-$991.8 million) are expected to come from totally excluding any funding of private medical activity. New rules will be introduced on diagnostic testing, coupled with price monitoring.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight